Until more evidence, reserve the use of perc LAAO in cardiomyopathies to the very few patients with recurrent uncontrollable bleeding

Even if we see an HCM patient post LAAO (indication: alternative to AC), we still recommend a DOAC

x.com/MasriAhmadMD/s…

#CardioTwitter

Great day OHSU School of Medicine OHSU Department of Surgery OHSU Doernbecher Children's Hospital OHSU Knight Cardio sponsoring and hosting TheMarfanFoundation The VEDS Movement Loeys-Dietz Syndrome walk! What a great day to bring the community together!

Can OM be an antidote when things go wrong? Low dose dobutamine rescues the systolic dysfunction in highly symptomatic patients which is thankfully not common

Amazing presentation by Brett Sperry, MD detailing tafamidis long term data 1)Continued survival benefit in the longterm. 2) stabilized eGFR compared to placebo 3) reduced decline in health status and functional capacity in octogenarians 4) benefit in NYHA3

A rare case of haemorrhagic left atrial bouncing ball #myxoma by EHJ Editor-in-Chief
Heng Zhang et al. doi.org/10.1093/eurhea…
EACVI President Edgar Argulian Ritu Thamman MD Ekaterina Stellbrink
Tuğba Kemaloğlu Öz, A/Prof RODRIGO BAHIENSE VISCONTI Julia Grapsa Alessia Gimelli Hooman Bakhshi Alex Felix Kevin Domingues

My co-director @steveommen will kick off Day 2 of #HCMSummit8 with a talk on #heartfailure in #obstructiveHCM . We're less than 5 months away & seats are now very limited—register soon to secure your spot: hcmsummit.org/tickets. #hcm #cardiotwitter #hypertrophiccardiomyopathy

#ResearchLetter : Use of a novel transthyretin aggregate detector probe suggests that ATTR plasma contains a unique biomarker that decreases in response to treatment #AHAJournals ahajournals.org/doi/10.1161/CI…

ATTR-CM Emerging Markets meeting in Instanbul is starting!

124 participants from around the world are here to become Amyloidosis champions in their home country

Sharmila Dorbala discussing physiology of amyloid infiltration in the myocardium and benefits / pitfalls of PYP imaging

ATTR-CM Emerging Markets conference in Istanbul

💥💥A few spots left💥💥
Starting your CV fellowship in July? Sign up for the Methodist DeBakey Boot Camp scheduled on Aug 9-11.🌟Hands-on & didactics sessions.
Apply by 6/14:
forms.office.com/r/UC2ts5EnS0
#ACCFIT #Cardiotwitter #EchoFirst #RadialFirst #EPeeps
Watch video in this 🧵!

Spot diagnosis

Presented at the HFA meeting and simultaneous publication in @JAMA. In this study of 4 large cohorts (ARIC, MESA, REGARDS, WHI) pooling >23,000 self-reported Black participants, the prevalence of the V142I variant was 3.2%. jamanetwork.com/journals/jama/…

Nominations for HFC Site-Based Research Awards are OPEN! Awards presented at AHAMeetings #AHA24

Submit your nominations before AUG 1st🥇to promote the work of top PIs, CRCs, and sites.

hfcollaboratory.com/nomination/
Mona Fiuzat Christopher O'Connor Vanessa Blumer, MD, FACC Mitchell Psotka Mariell Jessup

📖 Read a new #review about invasive management of #HypertrophicCardiomyopathy 👉 onlinecjc.ca/article/S0828-… #HCM #CJC

Don't miss #ASNC2024 ! Experience unforgettable networking events, including the ASNC Party Cruise. Enjoy an evening of appetizers🍤, cocktails🍸, & live music🎶 while witnessing Austin's iconic bat emergence!🦇

Register now & add it to your program:
👉bit.ly/44MMJzO

📖 Read about #MitralValve interventions for #HypertrophicObstructiveCardiomyopathy in the newest focus issue of #CJC ! 👉 onlinecjc.ca/article/S0828-… #HCM #HOCM

In the SEQUOIA-HCM trial, researchers evaluated the efficacy and safety of aficamten in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Read the full trial results and Plain Language Summary: nej.md/3wmDzyl

✍️ Read a new #review in #CJC : Trans-Atlantic Differences in Approach to Sudden Death Prevention in #HypertrophicCardiomyopathy 👉 onlinecjc.ca/article/S0828-… #HCM

✨Today, we celebrated our Cardiology Fellowship Class of 2024✨ We can't wait to see you shine in your future subspecialties!
Congratulations to our graduates & their families🎓👏

Cardiomyopathy is a disease of the heart muscle that can occur at any age and can be passed down genetically. It is a predominant cause of sudden cardiac death in people under the age of 35.

#ThinkCardiomyopathy #CardiomyopathyAwareness #Cardiomyopathy2024 #ThinkCM